Tenax Therapeutics: Will It Or Won't It?

(RTTNews) - Just 2 more days until the end of this month, and if Tenax Therapeutics Inc. (TENX) is able to keep to its deadline, a major catalyst is coming its way.

The company's lead product candidate is Levosimendan, and it is under phase III trial for reduction in morbidity and mortality of cardiac surgery patients at risk of low cardiac output syndrome, dubbed LEVO-CTS.

Low cardiac output syndrome, or LCOS, which refers to a condition of imbalance between oxygen supply and demand in the tissues, is reported to occur in 5-10% of patients undergoing cardiac surgery, and is associated with 10-15 fold higher mortality. There are no approved pharmacologic therapies for management or prevention of post-cardiotomy LCOS.

The LEVO-CTS trial has enrolled a total of 880 patients. The enrollment in the trial was completed last November, and at that time, the company said it will report top-line data in January 2017.

Now, with just two days left for the deadline to pass by, it is worth keeping a close watch on Tenax.

Will Tenax stick to January 30 deadline to report the LEVO-CTS data? If so, will the results be heartening or depressing for investors?

TENX closed Friday's (Jan.27th) trading at $2.16, up 19.34%.